Details

Autor(en) / Beteiligte

• Lecumberri, Ramón
• Krsnik, Isabel
• Askari, Elham
• Sirvent, Maialen
• González-Pérez, Marta S.
• Escalante, Fernando
• Pradillo, Virginia
• Tamariz, Luis E.
• Cánovas, Verónica
• Alegre, Adrián
• Gironella, Mercedes
• González-García, María E.
• Infante, María S.
• Lakhwani, Sunil
• Martínez-Bilbao, Cristina
• Dourdil, Victoria
• Ramírez-Payer, Ángel
• Sarrá, José
• Cibeira, M. Teresa

Titel

Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature

Ist Teil von

• Amyloid, 2020-07, Vol.27 (3), p.163-167

Ort / Verlag

England: Taylor & Francis

Erscheinungsjahr

2020

Beschreibungen/Notizen

• Management of patients with relapsed or refractory (R/R) AL amyloidosis is complex. Some initial reports have shown positive results with daratumumab in heavily pre-treated AL amyloidosis patients. In this retrospective multicentric study, 38 patients (mean age 64 ± 9 years) with R/R AL amyloidosis treated with daratumumab were included. Cardiac and renal involvement was present in 76 and 74% of patients, and 42% had ≥3 organs involved. Median number of previous lines of therapy was 2 (range 1-8). Overall hematological response was 72%, including 28% complete responses. The median time to first hematological response was 2 weeks. A high-quality response (≥very good partial response) was obtained in 65% of patients who had never achieved such depth of response previously. Hematological responses were more frequent among patients receiving daratumumab as second-line therapy compared to subsequent therapies (92 vs. 61%). Cardiac and renal organ response rates were 37 and 59%. At 12 months, overall and progression-free survival were 59% (95%CI: 0.36-0.77) and 52% (95%CI: 0.29-0.70), respectively. Daratumumab is a safe and effective drug in the treatment of R/R AL amyloidosis and should be considered early in the course of the disease.